In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1

(NIH/National Cancer Institute) Findings from a phase 2 clinical trial show that the drug selumetinib improves outcomes for children with the genetic disorder neurofibromatosis type 1 (NF1). In the trial, selumetinib shrank the inoperable tumors that develop with NF1 called plexiform neurofibromas, and children experienced reduced pain, improved function, and better overall quality of life after receiving the treatment. The trial was led by intramural researchers at the National Cancer Institute, part of the National Institutes of Health.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news